Beranda › Leukemia Mielomonositik Kronis
Uji klinis Leukemia Mielomonositik Kronis yang merekrut di AS
42 studi untuk Leukemia Mielomonositik Kronis merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Houston, TX16 studi
- Seattle, WA10 studi
- Boston, MA7 studi
- Baldwin Park, CA6 studi
- New York City, NY6 studi
- Mountain View, CA6 studi
- Rochester, MN6 studi
- Durham, NC5 studi
- Birmingham, AL4 studi
- Miami, FL4 studi
- Atlanta, GA4 studi
- Tampa, FL4 studi
- Columbus, OH4 studi
- Portland, OR3 studi
- Charleston, SC3 studi
- Los Angeles, CA3 studi
- Nashville, TN3 studi
Berdasarkan negara bagian
- Alabama4 studi
- California12 studi
- Florida8 studi
- Georgia4 studi
- Maryland3 studi
- Massachusetts7 studi
- Minnesota7 studi
- New York8 studi
- North Carolina5 studi
- Ohio5 studi
- Oregon3 studi
- Pennsylvania4 studi
- South Carolina3 studi
- Tennessee3 studi
- Texas18 studi
- Washington10 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Menerima pesertaFase 1
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06904066Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT03418038CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT04375631(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT04996875Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT03683433A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
Menerima pesertaFase 2Sukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT06566742Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Menerima pesertaFase 2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT03383575Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT07249346Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Agu 2026 · NCT06523556Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT07033598TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Menerima pesertaFase 1
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT07302776Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT07143669Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
Menerima pesertaFase 2/3Sukarelawan sehat diterima
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT04708054Pacritinib in CMML
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT06159491Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Menerima pesertaFase 1/2
Usia 12 hingga 80 · Semua jenis kelamin · Diperbarui 7 Agu 2026 · NCT05092451Personalized NK Cell Therapy in CBT
Menerima pesertaFase 2
Usia 15 hingga 80 · Semua jenis kelamin · Diperbarui 30 Jul 2026 · NCT02727803Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Jul 2026 · NCT07046078Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Jul 2026 · NCT07128381Registry of Older Patients With Cancer
Menerima pesertaStudi observasional
Usia 65 ke atas · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT01137825Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
Menerima pesertaFase 2
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT06815003211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Menerima pesertaFase 1/2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 22 Jun 2026 · NCT03128034211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Menerima pesertaFase 1/2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 22 Jun 2026 · NCT03670966Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Jun 2026 · NCT05549661Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
Menerima pesertaFase awal 1
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 3 Jun 2026 · NCT03964506Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Menerima pesertaFase 2Sukarelawan sehat diterima
6 Months · Semua jenis kelamin · Diperbarui 29 Mei 2026 · NCT04195633Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.